Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifinatamab deruxtecan + atezolizumab
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ifinatamab deruxtecan + atezolizumab is an investigational **combination regimen** being evaluated primarily in extensive-stage small cell lung cancer (ES-SCLC)[1][3]. The regimen combines ifinatamab deruxtecan (I-DXd), a **B7-H3–directed antibody-drug conjugate (ADC)** utilizing a DXd (deruxtecan) topoisomerase I inhibitor payload, with atezolizumab, an **immune checkpoint inhibitor** targeting PD-L1. I-DXd is designed to deliver a cytotoxic payload specifically to B7-H3-expressing tumor cells, while atezolizumab potentiates antitumor immunity by blocking the PD-1/PD-L1 axis. The combination aims to synergize targeted cytotoxicity with immune activation. This combination is being developed by Daiichi Sankyo and Merck, with Daiichi Sankyo responsible for manufacturing[4][6]. The main indication under development is as first-line induction or maintenance therapy or for relapsed ES-SCLC[1][3].
- Other names
- ifinatamab deruxtecan + atezolizumab
02
Targets
B7-H3CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on ifinatamab deruxtecan + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifinatamab deruxtecan + atezolizumab.